Remedy publishes the financial statements release, two business reviews and the half-year review according to the disclosed annual schedule.
|Silent period and closed window||January 11 – February 10, 2023|
|Financial Statements Release 2022||February 10, 2023|
|Annual Report, Financial Statements and Board of Directors’ Report 2022||Week 12 / 2023|
|Silent period and closed window||March 27 – April 26, 2023|
|Annual General Meeting 2023||April 13, 2023|
|Business Review for January-March 2023||April 26, 2023|
|Silent period and closed window||July 12 – August 11, 2023|
|Half-year Financial Report for January-June 2023||August 11, 2023|
|Silent period and closed window||October 1 – October 31, 2023|
|Business Review for January-September 2023||October 31, 2023|
Regularly published financial reports are always preceded by a silent period of 30 days, during which Remedy does not issue statements on the financial position, business operations, markets or prospects.
During the silent period, the senior management of the company does not meet with investors, analysts or other capital market representatives, nor do they give interviews on the financial position of the company.